Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples